Cargando…

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications

OBJECTIVES: This paper aims to assess the methodological quality of economic evaluations included in Belgian reimbursement applications for Class 1 drugs. MATERIALS AND METHODS: For 19 reimbursement applications submitted during 2011 and Spring 2012, a descriptive analysis assessed the methodologica...

Descripción completa

Detalles Bibliográficos
Autor principal:	Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875546/ https://www.ncbi.nlm.nih.gov/pubmed/24386474 http://dx.doi.org/10.1371/journal.pone.0085411

Ejemplares similares

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Health Economic Assessment: A Methodological Primer
por: Simoens, Steven
Publicado: (2009)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Assessing the sensitivity and representativeness of the Belgian Sentinel Network of Laboratories using test reimbursement data
por: Berger, Nicolas, et al.
Publicado: (2016)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Critical Reflections on Reimbursement and Access of Advanced Therapies
por: Simoens, Steven, et al.
Publicado: (2022)

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions
por: Simeonidis, Stavros, et al.
Publicado: (2019)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Design & Analysis of Clinical Trials for Economic Evaluation & Reimbursement
por: Khan, Iftekhar
Publicado: (2015)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
por: Liu, Liu, et al.
Publicado: (2022)

Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments
por: Weir, Christopher J., et al.
Publicado: (2022)

Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review
por: Yan, Juntao, et al.
Publicado: (2023)

Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data
por: Meurisse, Marjan, et al.
Publicado: (2022)

Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service
por: Russo, Pierluigi, et al.
Publicado: (2022)

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Financial based agreements and performance based agreements: the Belgian experience
por: Pauwels, Kim, et al.
Publicado: (2015)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Health Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria
por: Simoens, Steven
Publicado: (2010)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening
por: Langer, Astrid, et al.
Publicado: (2012)

By Belgians for Belgians
por: Childers, M. A.
Publicado: (1915)

Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps
por: Li, Hongchao, et al.
Publicado: (2022)

Changes in Medicare Reimbursement in Colorado: Impact on Physicians' Economic Behavior
por: Rice, Thomas, et al.
Publicado: (1982)

Methodological basics and evolution of the Belgian health interview survey 1997–2008
por: Demarest, Stefaan, et al.
Publicado: (2013)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Nosocomial infection surveillance in Belgian ICUs: aim and methodology of the feedback
por: Hanique, G, et al.
Publicado: (1998)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

Health Economics of Antibiotics
por: Simoens, Steven
Publicado: (2010)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Contemplating Health Economics, Coding and Reimbursement in Orthotics, Prosthetics and Pedorthics
por: Highsmith, MJ, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_go9u97n1q6hvarpe0pgu1bnphe